Tech Company Financing Transactions
Oorja Bio Funding Round
Westlake Village BioPartners and private investors participated in a $30 million Series A funding round for Oorja Bio. The funding round closed on 5/20/2026.
Transaction Overview
Company Name
Announced On
5/20/2026
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series A
Investors
Westlake Village BioPartners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance the clinical development of ORJ-001, a first-in-class therapeutic to treat idiopathic pulmonary fibrosis (IPF), and build a pipeline of assets to address other diseases involving fibrosis or cardiopulmonary function.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Texas Medical Center, 2450 Holcombe Blvd 1.320
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Undisclosed
Website
Email Address
Overview
Oorja's goal is to develop groundbreaking therapies for cardiopulmonary and fibrotic disorders that target the underlying pathophysiology of disease. By addressing key pathways, our medicines promote cellular repair, reverse and or remodel fibrotic tissue, going beyond symptom management to establish a new therapeutic standard of care.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sujay Kango
Chief Medical Officer
Janethe de Oliveira Pena
VP - Bus. Development
Connie Coulomb
Browse more venture capital transactions:
Prev: 5/20/2026: Eyst Technology venture capital transaction
Next: 5/20/2026: Rightbrain AI venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs